3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
177
HER2-positive Breast Cancer
16
Neoplasms
11
Neoplasm Metastasis
10
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Colonic Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Rectal Neoplasms
3
Pathologic Complete Response
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
HER2-positive Early Breast Cancer
3
Esophageal Neoplasms
3
Breast Neoplasms, Male
3
Biliary Tract Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Locally Advanced Breast Cancer
2
Interventions
Gemcitabine
60
Cisplatin
38
Oxaliplatin
30
Capecitabine
28
Fluorouracil
21
Leucovorin
19
pembrolizumab
11
Irinotecan
11
durvalumab
9
130-nm albumin-bound paclitaxel
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Platinum
6
Magnetic Resonance Spectroscopy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Taxes
5
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Carboplatin
5
Docetaxel
4
Biopsy
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Paclitaxel
3
Lapatinib
3
Interleukin-12 Subunit p35
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gallbladder Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled